Journal Home > Volume 8 , Issue 2
Journal of Neurorestoratology 2020, 8(2): 93-103 https://doi.org/10.26599/JNR.2020.9040011
Review Article | Open Access | Issue | Published: 04 August 2020

The cell repair research for Parkinson’s disease: A systematic review

Show Author's Information Chao Chen1,2,§,  Qingfa Chen2,§,  Yan Liu1,  Chongyang Zhang3,  Kaixiang Zhu3,  Xue Li4,  Haitao Xie5( ),  Rui Zhang6( )
State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
The Institute for Tissue Engineering and Regenerative Medicine, Liaocheng People’s Hospital and Liaocheng Clinical School of Shandong First Medical University, Liaocheng 252004, Shangdong, China
NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
Research Service Office, Liaocheng People’s Hospital, Liaocheng 252004,Shandong, China
Centre for Research, Xiankangda Biotech Corporation, Dongguan 523808, Guangdong, China
Department of Neurology, Liaocheng People’s Hospital, Liaocheng 252004, Shandong, China

§ These authors contributed equally to this work.

Keywords:
Parkinson’s disease, cell transplantation, Unified Parkinson’s Disease Rating Scale (UPDRS), systematic review
Cite this article:
Chen C, Chen Q, Liu Y, et al. The cell repair research for Parkinson’s disease: A systematic review. Journal of Neurorestoratology, 2020, 8(2): 93-103. https://doi.org/10.26599/JNR.2020.9040011
Download citation
EndNote(RIS)
BibTeX

665

Views

39

Downloads

Citations

7

Crossref

6

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article
Background and Objective:

Parkinson’s disease (PD) is a common neurodegenerative disease. Previous studies have demonstrated the effect of cell-based therapies, but their clinical efficacy and safety have not been evaluated. This review protocol aimed to systematically evaluate the effect of stem cell therapy in patients with PD and to develop an evidence base for guiding policy and practice.

Methods:

PubMed, Embase, MedlinePlus, The Lancet and Brain were searched over the period January 2001 to October 2019. The keywords used for searching were "Parkinson’s disease" and "cell therapy" and "mesenchymal stem cells" and "embryonic stem cells" and "brain-derived neural stem cells" and "neural progenitor cells" . The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and a measurement tool, Assessment of Multiple Systematic Reviews (AMSTAR), to assess systematic reviews were used to assess the reporting quality and methodological quality. Data extracted included study details, participant details, intervention details and outcome.

Results:

Nine valid research papers were screened out by systematic analysis. These nine studies were carried out in different countries, with different populations and cell types. According to evaluation methods used, all of the transplantation therapies reported can improve the symptoms of PD patients.

Conclusions:

Cell transplantation is a potential treatment option for PD. More studies with strict study design, larger sample sizes, and longer follow-up are needed in the future.


menu
Abstract
Full text
Outline
About this article

The cell repair research for Parkinson’s disease: A systematic review

Show Author's information Chao Chen1,2,§, Qingfa Chen2,§, Yan Liu1, Chongyang Zhang3, Kaixiang Zhu3, Xue Li4, Haitao Xie5( ), Rui Zhang6( )
State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
The Institute for Tissue Engineering and Regenerative Medicine, Liaocheng People’s Hospital and Liaocheng Clinical School of Shandong First Medical University, Liaocheng 252004, Shangdong, China
NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
Research Service Office, Liaocheng People’s Hospital, Liaocheng 252004,Shandong, China
Centre for Research, Xiankangda Biotech Corporation, Dongguan 523808, Guangdong, China
Department of Neurology, Liaocheng People’s Hospital, Liaocheng 252004, Shandong, China

§ These authors contributed equally to this work.

Abstract

Background and Objective:

Parkinson’s disease (PD) is a common neurodegenerative disease. Previous studies have demonstrated the effect of cell-based therapies, but their clinical efficacy and safety have not been evaluated. This review protocol aimed to systematically evaluate the effect of stem cell therapy in patients with PD and to develop an evidence base for guiding policy and practice.

Methods:

PubMed, Embase, MedlinePlus, The Lancet and Brain were searched over the period January 2001 to October 2019. The keywords used for searching were "Parkinson’s disease" and "cell therapy" and "mesenchymal stem cells" and "embryonic stem cells" and "brain-derived neural stem cells" and "neural progenitor cells" . The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and a measurement tool, Assessment of Multiple Systematic Reviews (AMSTAR), to assess systematic reviews were used to assess the reporting quality and methodological quality. Data extracted included study details, participant details, intervention details and outcome.

Results:

Nine valid research papers were screened out by systematic analysis. These nine studies were carried out in different countries, with different populations and cell types. According to evaluation methods used, all of the transplantation therapies reported can improve the symptoms of PD patients.

Conclusions:

Cell transplantation is a potential treatment option for PD. More studies with strict study design, larger sample sizes, and longer follow-up are needed in the future.

Keywords: Parkinson’s disease, cell transplantation, Unified Parkinson’s Disease Rating Scale (UPDRS), systematic review

References(18)

[1]
T Pringsheim, N Jette, A Frolkis, et al. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014, 29(13): 1583-1590.
DOI Google Scholar
[2]
LX Meng, X Yuan, XB Cao, et al. The gut-brain axis in the pathogenesis of Parkinson's disease. Brain Sci Adv. 2019, 5(2): 73-81.
DOI Google Scholar
[3]
FB Han, D Baremberg, JY Gao, et al. Development of stem cell-based therapy for Parkinson's disease. Transl Neurodegener. 2015, 4: 16.
DOI Google Scholar
[4]
TB Stoker, RA Barker. Regenerative therapies for Parkinson's disease: An update. BioDrugs. 2018, 32(4): 357-366.
DOI Google Scholar
[5]
Y Yang, SH Maio, RS Zhou, et al. The development of visual neuroimaging research of acupuncture in the treatment of Parkinson’s disease. Brain Sci Adv. 2019, 5(3): 161-168.
DOI Google Scholar
[6]
HH Yoon, J Min, SR Jeon. Optogenetics to restore neural circuit function in Parkinson's disease. J Neurorestoratology. 2018, 1(1): 5-9.
DOI Google Scholar
[7]
JH Kordower, YP Chu, RA Hauser, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008, 14(5): 504-506.
DOI Google Scholar
[8]
M Canesi, R Giordano, L Lazzari, et al. Finding a new therapeutic approach for no-option Parkinsonisms: mesenchymal stromal cells for progressive supranuclear palsy. J Transl Med. 2016, 14(1): 127.
DOI Google Scholar
[9]
NK Venkataramana, SK Kumar, S Balaraju, et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Transl Res. 2010, 155(2): 62-70.
DOI Google Scholar
[10]
CR Freed, PE Greene, RE Breeze, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001, 344(10): 710-719.
DOI Google Scholar
[11]
W Li, E Englund, H Widner, et al. Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci USA. 2016, 113(23): 6544-6549.
DOI Google Scholar
[12]
LG Leng, ZM Tian. Transplantation of neural precursor cells in the treatment of parkinson disease: an efficacy and safety analysis. Turk Neurosurg. 2016, 26(3): 378-383.
Google Scholar
[13]
A Brazzini, R Cantella, A De la Cruz, et al. Intraarterial autologous implantation of adult stem cells for patients with Parkinson disease. J Vasc Interv Radiol. 2010, 21(4): 443-451.
DOI Google Scholar
[14]
F Yin, ZM Tian, S Liu, et al. Transplantation of human retinal pigment epithelium cells in the treatment for parkinson disease. CNS Neurosci Ther. 2012, 18(12): 1012-1020.
DOI Google Scholar
[15]
Z Kefalopoulou, M Politis, P Piccini, et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol. 2014, 71(1): 83-87.
DOI Google Scholar
[16]
A Schrag, Y Ben-Shlomo, NP Quinn. Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ. 2000, 321(7252): 21-22.
DOI Google Scholar
[17]
B Kis, A Schrag, Y Ben-Shlomo, et al. Novel three- stage ascertainment method: prevalence of PD and Parkinsonism in South Tyrol, Italy. Neurology. 2002, 58(12): 1820-1825.
DOI Google Scholar
[18]
P Hagell, P Brundin. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J Neuropathol Exp Neurol. 2001, 60(8): 741-752.
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 27 April 2020
Revised: 25 May 2020
Accepted: 15 June 2020
Published: 04 August 2020
Issue date: June 2020

Copyright

© The authors 2020

Acknowledgements

This research was funded by the National Natural Science Foundation of China (Grant No. 81800980), and by the National Natural Science Foundation of Shandong Province (Grant No. ZR2019PC017).

Rights and permissions

This article is published with open access at http://jnr.tsinghuajournals.com

Return